174 related articles for article (PubMed ID: 20563566)
21. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
[TBL] [Abstract][Full Text] [Related]
22. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
[TBL] [Abstract][Full Text] [Related]
23. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
Ueno H; Kaniwa N; Okusaka T; Ikeda M; Morizane C; Kondo S; Sugiyama E; Kim SR; Hasegawa R; Saito Y; Yoshida T; Saijo N; Sawada J
Br J Cancer; 2009 Mar; 100(6):870-3. PubMed ID: 19293806
[TBL] [Abstract][Full Text] [Related]
24. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Mitra AK; Kirstein MN; Khatri A; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK
Pharmacogenomics; 2012 Jul; 13(9):1009-21. PubMed ID: 22838949
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Shord SS; Patel SR
J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
[TBL] [Abstract][Full Text] [Related]
26. Does saturable formation of gemcitabine triphosphate occur in patients?
Tham LS; Wang LZ; Soo RA; Lee HS; Lee SC; Goh BC; Holford NH
Cancer Chemother Pharmacol; 2008 Dec; 63(1):55-64. PubMed ID: 18305939
[TBL] [Abstract][Full Text] [Related]
27. Integrating pharmacogenetics into gemcitabine dosing--time for a change?
Ciccolini J; Mercier C; Dahan L; André N
Nat Rev Clin Oncol; 2011 Feb; 8(7):439-44. PubMed ID: 21304503
[TBL] [Abstract][Full Text] [Related]
28. Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer.
Wang LR; Liu J; Huang MZ; Xu N
J Zhejiang Univ Sci B; 2007 May; 8(5):307-13. PubMed ID: 17542057
[TBL] [Abstract][Full Text] [Related]
29. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
Wang L; Wu X; Huang M; Cai J; Xu N; Liu J
Cancer Chemother Pharmacol; 2007 Jul; 60(2):211-8. PubMed ID: 17124596
[TBL] [Abstract][Full Text] [Related]
31. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
[TBL] [Abstract][Full Text] [Related]
32. [Clinical development in gemcitabine and its clinical pharmacological profile].
Tsukagoshi S; Taguchi T
Gan To Kagaku Ryoho; 1999 Jun; 26(7):877-83. PubMed ID: 10396313
[TBL] [Abstract][Full Text] [Related]
33. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Yonemori K; Ueno H; Okusaka T; Yamamoto N; Ikeda M; Saijo N; Yoshida T; Ishii H; Furuse J; Sugiyama E; Kim SR; Kikura-Hanajiri R; Hasegawa R; Saito Y; Ozawa S; Kaniwa N; Sawada J
Clin Cancer Res; 2005 Apr; 11(7):2620-4. PubMed ID: 15814642
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine in non-small cell lung cancer.
Sørensen JB
Lung Cancer; 1995 Apr; 12 Suppl 1():S173-5. PubMed ID: 7551926
[TBL] [Abstract][Full Text] [Related]
35. [Gemcitabine in the treatment of advanced non-small cell lung cancer: report of one case].
Liu AH; Wang XS; Zhou Y; Duan EY; Wu YX
Di Yi Jun Yi Da Xue Xue Bao; 2002 Jan; 22(1):94-5. PubMed ID: 12390863
[TBL] [Abstract][Full Text] [Related]
36. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine shows promise as combination agent in NSCLC.
Oncology (Williston Park); 1996 Sep; 10(9):1311. PubMed ID: 9052981
[No Abstract] [Full Text] [Related]
38. Gemcitabine and the blood brain barrier.
Davis JR; Fernandes C; Zalcberg JR
Aust N Z J Med; 1999 Dec; 29(6):831-2. PubMed ID: 10677133
[No Abstract] [Full Text] [Related]
39. More is better but ... how is best: are milligrams over hours better than grams over minutes? The case of gemcitabine.
Pollera CF
J Clin Oncol; 1997 May; 15(5):2172-4. PubMed ID: 9164234
[No Abstract] [Full Text] [Related]
40. High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation.
Xu J; Zhou Y; Zhang J; Chen Y; Zhuang R; Liu T; Cai W
Clin Chim Acta; 2012 Aug; 413(15-16):1284-7. PubMed ID: 22546611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
